Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Investor Presentation January 13, 2025 Disclaimer This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking ...

A video of the Ekso Voice Agent demonstration can be accessed here. About NVIDIA Connect NVIDIA Connect is a selective program that brings together emerging and established technology companies to accelerate product development and increase cost efficiency. Members gain specialized training, priority engineering support, and exclusive access to NVIDIA's advanced development kits, GPU platforms, and global ecosystem, helping them deliver next-generation solutions in AI and high-performance computing. AI voic ...

AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety About Ekso Bionics® Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Based upon its industry- leading expertise, the Company focuses on improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human ...

SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The ...

SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company’s common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Comp ...

Company unveils a strategic initiative to build the world’s first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics’ proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced ...

Ekso Bionics (EKSO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.09%. A quarter ago, it was expected that this robotic exoskeleton company would post a loss of $0.06 per share when it actually produced a loss of $0.14, delivering a surprise of -133.33%.Over the last four quarters, the c ...

Ekso Bionics (EKSO) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsJerome Wong - Chief Financial OfficerScott Davis - Chief Executive OfficerBen Haynor - Managing Director Conference Call Participants Swayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Greetings, and welcome to the Ekso Bionics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question ...

Ekso Bionics (EKSO) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Stephen Kilmer - Investor RelationsJerome Wong - Chief Financial OfficerScott Davis - Chief Executive OfficerBen Haynor - Managing Director Conference Call Participants Swayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Greetings, and welcome to the Ekso Bionics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question ...

Ekso Bionics (EKSO) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the Ekso Bionics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Stephen Comer of Investor Relations. Thank you. You may begin. Speaker1 Thank you, operator, and good af ...